Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

C-Path device director

This article was originally published in The Gray Sheet

Executive Summary

Ellen Feigal, MD, has been appointed director of medical devices and imaging of the Critical Path Institute (C-Path) in Tucson, Ariz., announced April 24. C-Path is a partner to FDA's Critical Path initiative to speed drugs, devices and diagnostics to market (1"The Gray Sheet" March 27, 2006, p. 5). Feigal worked at the National Cancer Institute from 1992 to 2004, where she spent her last three years as director of the Division of Cancer Treatment and Diagnostics. Currently, she is on sabbatical from the personalized medicine-focused Translational Genomics Research Institute (TGen), where she is VP-clinical sciences and deputy scientific director. Additionally, Jeffrey Cossman, MD, was appointed as C-Path's chief scientific officer April 18. Cosson has served as a senior scientist at the National Cancer Institute and the National Institutes of Health, and most recently was VP and medical director at genomics company Gene Logic...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT023492

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel